Showing 1–11 of 11 · Pharmacy & medicines management
FY2026 revenue $19.46bn (+4.9%); operating margin 11.6%; net income $1.15bn.
Continuing operations; net income from continuing operations $1.42bn (+29%).
FY2025 revenue €649.2m (-0.8%); operating margin 4.7%; net income €9.4m.
Balance sheet figures not captured from release.
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
FY2025 revenue $1.18bn (+6.5%); operating margin 0.4%; net income $2.1m.
Cash $196.5m; debt $167.6m.
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
Parent Telstra Group (TLS.AX) FY2026 group net income about A$2.40bn (+2.7%).
Revenue and operating profit not yet captured, so financial health not assessed.
Part of TELUS (T.TO).
Latest full-year results not yet captured by HSH.
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
Parent Wolters Kluwer (WKL.AS) group FY2025 revenue €6.12bn (+3.5%); operating margin 28.3%; net income €1.31bn.
Health division revenue €1.60bn (+5% organic); net debt €4.02bn.